Newsletter

SAGE Clinical Trial Fails

Sage Therapeutics announced disappointing results on its late-stage clinical trial of a brexanolone treament for a seizure disorder called super-refractory status epilepticus (SRSE). Right now there is no U.S. drug approved for the condition. Sonal caught the news at 6:15 am with a level 2 alert before the stock price fell from $88.22 to $74.65. […]

Read more...

ALNM Holds Gains Over Five Days

Alnylam Pharmaceuticals reported exciting stage 3 clinical trial results on September 20. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year.   Sonal sent out a level 2 alert at 7 am, and the next trade was at $93.50 during pre-market trading. […]

Read more...